Baltimore claims Biogen ‘bribed’ PBMs to favor its pricey MS drug over generics

Taking stock of the drug industry, from the lab to the medicine chest

September 24, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

APStock STAT+ | Baltimore claims Biogen 'bribed' PBMs to favor its pricey MS drug over generics The lawsuit contended Biogen paid the companies to "manipulate" placement of generic versions of Tecfidera on their formularies. By Ed Silverman STAT+ | Regeneron's Eylea biosimilar fight heats up Amgen can bring its drug to the market "at risk," meaning before patent litigation is decided, although that decision, in itself, would be a gamble. By Adam Feuerstein STAT+ | Amid push to redefine itself, Sanofi names new chief scientific officer Mike Quigley is formerly the CEO of startups Dualitas Therapeutics and Therini Bio, and senior vice president of research biology at Gilead. By Matthew Herper Dave Hernandez STAT+ | The U.S. has relied on cheap, effective generic drugs for 40 years. Now that promise is under threat Generic drugs now fill 9 out of every 10 prescriptions in America, and have saved people trillions. By Leslie Walker and Dan Gorenstein STAT+ | Novartis strikes AI drug development deal with Generate:Biomedicines Novartis is paying Generate $65 million up front, and milestone payments could exceed $1 billion. By Brittany Trang STAT+ | Risky bet by Biogen and UCB on systemic lupus drug appears to pay off, data show A Phase 2 study of dapirolizumab pegolin, conducted in 2018, was negative, although the companies saw enough evidence to keep investing in the drug.  By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser